A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma

Trial Profile

A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs CPI 0610 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Constellation Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2019.
    • 22 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top